The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis
Abstract FOLFIRINOX has been one of the first-line options for advanced pancreatic cancer, even though it induces significant adverse effects. Several institutions have begun using modified FOLFIRINOX to decrease its side effects and increase its tolerability. We systematically investigated the outc...
Guardado en:
Autores principales: | Hongxuan Tong, Zhu Fan, Biyuan Liu, Tao Lu |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/13b0bd8f9db545da901879f0ffc5158e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage
por: Pietro Carotenuto, et al.
Publicado: (2021) -
Acupuncture-related adverse events: systematic review and meta-analyses of prospective clinical studies
por: Dominik Irnich, et al.
Publicado: (2021) -
Benefits and adverse effects of sacubitril/valsartan in patients with chronic heart failure: A systematic review and meta‐analysis
por: Elodie Charuel, et al.
Publicado: (2021) -
Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial
por: Gunn Huh, et al.
Publicado: (2021) -
Efficacy and Treatment-Related Adverse Events of Romidepsin in PTCL Clinical Studies: A Systematic Review and Meta-Analysis
por: Jun Du, et al.
Publicado: (2021)